Malignant mesotheliomas are aggressive tumors resistant to current therapies^[@R2]^ and associated primarily with widespread commercial use of asbestos in the 20^th^ century^[@R1],[@R3]-[@R8]^. Approximately 27 million U.S. workers were exposed to asbestos from 1940-1979, and more thereafter^[@R4]^. In the U.S., mesothelioma incidence in different states varies from 1-2/10^6^ to 15/10^6^ depending on quantities of asbestos used, with \~3,000 deaths/year^[@R1]^. Despite asbestos abatement efforts, mesothelioma rates have remained stable in the U.S. since 1994 and will increase by 5-10% per year in Europe over the next 25 years^[@R1],[@R5]-[@R7]^. A marked increase in mesothelioma is predicted in developing countries, where asbestos usage is increasing exponentially^[@R8]^. Erionite shares physical characteristics with asbestos and also causes mesothelioma^[@R1]^. With increased urban development, exposure also occurs from disturbing asbestos- and erionite-containing soil^[@R9],[@R10]^.

Some individuals develop mesothelioma following exposure to small amounts of asbestos, while others exposed to heavy amounts do not^[@R1]^. We have reported mesothelioma clustering in some U.S. and Turkish families in which up to 50% of members developed mesothelioma^[@R11]^. This incidence far exceeds that observed in cohorts exposed to very high levels of asbestos (4.6%^[@R1]^).

Over the past 14 years, we studied prospectively high-risk mesothelioma families to identify a putative mesothelioma-susceptibility gene(s). We focused on two U.S. mesothelioma families, one in Wisconsin (W family) and one in Louisiana (L family), in which members were neither exposed to erionite nor had occupational exposure to asbestos, thus removing the confounding factor of heavy exposure to carcinogens known to cause a high incidence of mesothelioma. Family members developed various malignancies, although mesothelioma predominated ([Fig. 1a,b](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Array-CGH analysis of two tumors (one/family) uncovered alterations encompassing or adjacent to the *BAP1* locus in 3p21.1. In one tumor, W-III-06T (T=tumor), a transition in copy number occurred at or near the *BAP1* promoter, while in the second, L-III-18T, a focal deletion encompassing *BAP1* resided within a larger deletion ([Fig. 2a](#F2){ref-type="fig"}). We also performed linkage studies on germline DNA from each family. The largest linkage peak, reaching a maximum LOD score of 2.1, in a joint parametric analysis of the two families occurred at 3p21-22 ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Although the region implicated in linkage analyses assuming that only those with mesothelioma were affected was large and included many genes, a much smaller region was implicated by the array-CGH analysis, including a genomic imbalance beside the *BAP1* locus and an \~218-kb homozygous deletion that encompassed *BAP1*. Moreover, this smaller region was congruent with a smaller linkage region obtained in the W family assuming that all those with cancer, including kidney, ovary and early onset breast carcinomas, carried the same risk allele.

These findings, coupled with the fact that 3p21.1 is a site of recurrent chromosomal loss in sporadic mesotheliomas^[@R12]-[@R14]^ prompted our pursuit of this gene. BAP1 is a nuclear protein that enhances BRCA1-mediated inhibition of breast cancer cell proliferation, acting as a tumor suppressor in the BRCA1 growth control pathway and regulating proliferation by deubiquitinating host cell factor-1^[@R15],[@R16]^.

We sequenced *BAP1* in germline DNA from family W and found that six affected members (four with mesothelioma; two with breast or renal cancer) had identical mutations, whereas unaffected family members did not ([Fig. 1a](#F1){ref-type="fig"}). Mutation status was consistent with results of the linkage analysis, the latter additionally establishing that case W-III-10 (ovarian cancer) was a *BAP1* mutation carrier. The germline mutation in family W occurred at the intron 6/exon 7 boundary, with affected individuals having an A→G substitution at the -2 nucleotide consensus splice acceptor site ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Such alterations lead to exon skipping and disease-causing protein changes^[@R17],[@R18]^. Transfection of mammalian cells with a genomic construct containing exons 6-8, and with the intron 6 splice site mutation, resulted in an aberrant splice product lacking exon 7 ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}) and frameshift predicted to lead to a premature stop codon and nonsense-mediated decay.

Besides the somatic genetic alteration detected by array-CGH in sample W-III-06T, in tumor W-III-08T only mutant *BAP1* could be detected, consistent with loss of wild-type *BAP1* on the other homologue. Additionally, W-III-04T had both the splice site mutation and a 25-bp exon 4 deletion resulting in a frameshift and premature termination of BAP1 (p.I72fsX7) ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). Matched germline DNA lacked the deletion, indicating a somatic origin. Cloning of genomic PCR products encompassing exons 4-7 from tumor DNA suggested that the splice site mutation and deletion reside in different alleles, consistent with biallelic inactivation of *BAP1.*

In family L, germline DNA from three individuals with mesothelioma (one recently treated for uveal melanoma) and two with skin carcinomas exhibited a germline C/G to T/A transition in exon 16, creating a stop codon (p.Q684X) ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"}). There was complete concordance between *BAP1* mutation status and linkage analysis. Linkage analyses also revealed that L-II-03 (pancreatic cancer) was a mutation carrier.

Exome sequencing, using the Illumina HiSeq 2000 system, of germline DNA from two affected members of each family verified the splice site and nonsense mutations in family W and family L, respectively (not shown). Immunohistochemistry on mesotheliomas from L and W families revealed lack of BAP1 nuclear expression ([Fig. 3](#F3){ref-type="fig"}).

Although occupational histories did not suggest any obvious exposure in these families, we detected chrysotile asbestos in 5/5 homes where all affected family L members had lived (consistent with the high percentage of asbestos-containing houses in the town where the family resided); traces of tremolite and chrysotile asbestos were found in the home where all affected members of family W were raised ([Supplementary Figs. 3,4](#SD1){ref-type="supplementary-material"}). About 30 million U.S. homes contain asbestos^[@R4]^; both families lived in such homes. Living in an asbestos-containing home is associated with modest levels of exposure, as observed in patients who have not been occupationally exposed, a growing fraction of mesothelioma patients^[@R1]^.

Having linked *BAP1* mutations to familial mesothelioma, we next sequenced *BAP1* (17 exons/introns/promoter) in 26 germline DNAs from sporadic mesothelioma patients. All of them had reported asbestos exposure to the treating physician, although these claims were not verified by lung content or mineralogical analyses. Two of 26 had *BAP1* deletions: c.1832delC in exon 13 (p.P572fsX3) and c.2008-2011delTACT in exon 14 (p.Y627fsX9) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Both mutations result in a frameshift leading to a stop codon upstream of the region encoding the BAP1 nuclear localization signal ([Fig. 2b](#F2){ref-type="fig"}). When we investigated whether anything was unique about these two patients, we found that each had been treated for uveal melanoma 1 or 6 years before being diagnosed with mesothelioma. Of the remaining 24 sporadic mesotheliomas, none had uveal melanoma. Tumor DNA was available from 18 of the 26 sporadic mesothelioma patients: DNA sequencing revealed truncating *BAP1* mutations in 4/18 (22%) tumors ([Fig. 4a](#F4){ref-type="fig"}); BAP1 alterations in these tumors were supported by immunoblot analyses ([Fig. 4b](#F4){ref-type="fig"}). Also, 7/12 mesothelioma cell lines tested showed loss of BAP1 expression ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). Re-expression of BAP1 in BAP1-deficient mesothelioma cells markedly decreased colony-forming ability ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}), consistent with BAP1's known role in regulating tumor cell proliferation and viability^[@R15],[@R16]^.

Frequent somatic mutations of *BAP1* were reported in metastasizing uveal melanomas, with one case having a germline mutation^[@R19]^. An association between uveal melanoma, breast and ovarian cancer has been proposed^[@R20]^. Neither study uncovered any mesothelioma, possibly because those patients were not exposed to asbestos. A paper published while our manuscript was being reviewed reported somatic *BAP1* mutations in 23% of sporadic mesotheliomas^[@R21]^, which concurs with our findings in sporadic tumors. In addition, and most importantly, we demonstrate the presence of germline *BAP1* mutations in members of U.S. families that experience an extremely high incidence of mesothelioma, in spite of very modest exposure to asbestos; thus, our results point to *BAP1* as the first reported gene that may modulate mineral fiber carcinogenesis. Furthermore, we show that *BAP1* mutations are associated with a novel hereditary cancer syndrome that predisposes to mesothelioma, uveal melanoma and potentially other cancers. The incidence of uveal melanoma is 5-7/10^6^ in the U.S.^[@R22]^, similar to mesothelioma^[@R1]^. Therefore, it is exceedingly unlikely that the occurrence of both malignancies in the same individual would occur by chance, e.g., if we assume the two diseases are independent and the joint probability (estimated at 36 per trillion per year) follows a binomial distribution, then the likelihood of three (or more) cases appearing in the U.S. (population \~310 million) per year is 2.3 × 10^−7^.

The average age of diagnosis of uveal melanoma is 56, with 5-year survivals of 70-99% depending on tumor size and histology^[@R22]^. Mesothelioma is diagnosed later in life, and a 5-year survival is extremely rare and limited to patients diagnosed during the very early stages of tumor growth, when patients can undergo cytoreductive surgery^[@R1],[@R2]^. Altogether, we observed *BAP1* mutations in four uveal melanoma patients, three of whom subsequently developed mesothelioma; the fourth (L-II-18) died of metastatic uveal melanoma to the liver ([Fig. 1b](#F1){ref-type="fig"}), and DNA was not available. Thus, our findings suggest that uveal melanoma patients with germline *BAP1* mutations are at high risk of developing mesothelioma and should be closely monitored.

Our results provide the first demonstration that genetics influences the risk of mesothelioma, a cancer linked to mineral fiber carcinogenesis. As observed for BRCA1 and BRCA2, which account for only some hereditary breast carcinomas, it appears likely that in addition to *BAP1*, more genes will be found associated with elevated risk of mesothelioma. Indeed, among our 26 sporadic mesotheliomas -- and excluding malignancies common in the 6^th^-8^th^ decades of life, such as skin and prostate carcinomas -- nine had been diagnosed with one or more additional tumors ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Seven of 26 were females, and 2/7 also had uterine leiomyosarcoma, a malignancy with an incidence of \~10/10^6^ per year in the U.S.; one of them had also uveal melanoma, an unlikely coincidence.

In summary, we demonstrate the existence of a *BAP1*-related cancer syndrome characterized by mesothelioma, uveal melanoma and possibly other cancer types. We hypothesize that when individuals with *BAP1* mutations are exposed to asbestos, mesothelioma predominates. Alternatively, *BAP1* mutation alone may be sufficient to cause mesothelioma.
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![Pedigrees of two U.S. mesothelioma families. (**a**, **b**) Pedigrees showing family members with a germline mutation in *BAP1*, as confirmed by both sequencing and linkage analyses (orange) or by linkage analysis alone (yellow, *i.e.*, no DNA was available for sequencing); individuals without the mutation (green) and individuals for whom DNA was unavailable (blue) are also shown. Presence or absence of germline *BAP1* mutation is also indicated with + or − symbols, respectively. (**a**) Pedigree of family W showing presence or absence of germline mutation at *BAP1* consensus splice acceptor site. (**b**) Pedigree of family L showing presence or absence of germline nonsense mutation. The development of other tumor types ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) in these families may also be related to *BAP1* germline mutations. In family W, the presence of a breast cancer before age 45 and an ovarian cancer suggests that the *BAP1* mutation is associated with a hereditary form of breast/ovarian cancer, as might be expected given BAP1's relationship with the breast/ovarian cancer susceptibility gene product, BRCA1^[@R15]^. In family L, the skin cancers shown were squamous cell carcinomas. Available mesothelioma tumor specimens with germline splice site mutation and either somatic 25-bp deletion (W-III-04T), genomic alteration (W-III-06T), or loss of wild-type *BAP1* allele (W-III-08T) are indicated in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, as is the homozygous deletion of *BAP1* seen in mesothelioma specimen L-III-18T.](nihms-314867-f0001){#F1}

![Array-CGH analysis of two mesothelioma family members and schematic diagrams of predicted mutant BAP1 proteins. (**a**) Array-CGH showing focal deletion encompassing *BAP1* within a larger 3p deletion (tumor L-III-18T) and amplicon adjacent to *BAP1* locus (tumor W-III-06T). The *BAP1* gene resides at chr3:52,435,027-52,444,009, and the Agilent Human 244K chip contains two probes within the *BAP1* locus: A_16_P00704764 (chr3:52,438,014-52,438,066) and A_14_P128339 (chr3:52,443,209-52,443,268). In W-III-06T, the two *BAP1* probes displayed log~2~ ratios indicative of normal diploid DNA copy numbers, whereas the log~2~ ratios of two probes immediately centromeric of *BAP1* showed a transition to a higher copy number, indicating the start of an amplified region at or very near the *BAP1* promoter (zoomed-in image and further details shown in [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). In L-III-18T, the focal homozygous deletion encompassed the entire *BAP1* locus and was \~218 kb in size. (**b**) Schematic diagram of predicted truncations of BAP1 resulting from germline mutations observed in two mesothelioma families (W, L) as well as in two sporadic mesothelioma patients who previously had developed uveal melanomas (SP-002; SP-008).](nihms-314867-f0002){#F2}

![Immunohistochemistry on mesotheliomas from L and W families reveals lack of BAP1 nuclear expression and only weak, focal cytoplasmic BAP1 staining. (**a**) SP-024, sporadic mesothelioma with wild-type BAP1; note the normal nuclear expression of BAP1. (**b**) W-III-04, (**c**) L-III-18, and (**d**) W-III-06 represent mesotheliomas from patients with germline *BAP1* mutations: note lack of nuclear expression and weak cytoplasmic staining. All magnifications 400X. Bar = 100 μm.](nihms-314867-f0003){#F3}

![*BAP1* truncating mutations and aberrant protein expression in sporadic mesothelioma tumor biopsies. (**a**) Schematic diagram of predicted truncations of BAP1 in four sporadic mesotheliomas harboring *BAP1* mutations. Bracket at left indicates mutations in two different *BAP1* alleles in tumor sample SP-015. NLS, nuclear localization signal at carboxy-terminus of BAP1. Frameshift sequences are shown as thinner gray bars. (**b**) Immunoblot analysis on whole tumor cell lysates of the same four sporadic mesotheliomas with somatic *BAP1* mutations (lanes 2-5) and sporadic tumor lacking a *BAP1* mutation (lane 1). Sporadic mesotheliomas with somatic *BAP1* mutations show decreased expression of BAP1 compared to that seen in tumor without *BAP1* mutation. Note that in mesotheliomas, whole tumor cell lysates inevitably contain some normal stromal cells that may be responsible for the faint BAP1 signal detected. Also note the presence of additional, faster-migrating BAP1 band in sample shown in lane 4 (SP-013), suggesting the presence of a truncated form of BAP1. The BAP1 protein products predicted in tumors SP-001 and SP-015 were not observed, suggesting nonsense-mediated mRNA decay. The mutation in tumor SP-018 results in a predicted protein product only 15 amino acids smaller, which presumably precludes detection of a small change in molecular weight compared to wild-type BAP1. GAPDH was used as a loading control.](nihms-314867-f0004){#F4}
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